Drug safety notice: SGLT2 inhibitors

March 15, 2022

SGLT2 inhibitors are indicated in the management of type 2 diabetes and are a first line option for those patients with chronic heart failure or established atherosclerotic cardiovascular disease in combination with metformin.

There is a risk of diabetic ketoacidosis (DKA) with SGLT2 inhibitors and serious, life threatening and fatal cases of DKA have been reported. In several cases the presentation was atypical with only moderately elevated blood glucose levels.

In order to minimise the risk of DKA in patients on an SGLT2 inhibitor details within the SGLT2 inhibitors information sheet must be followed.

For more information please contact the pharmacy department on ext. 5263/3783.